Secukinumab does not show greater clinical efficacy than placebo in patients with moderate-to-severe Graves’ orbitopathy, according to the ORBIT study. Medscape News UK
Uncategorized
Dompé Doses First Patients in Europe and US in Phase 3 Study of Isocyclosporin for Atopic Keratoconjunctivitis
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé advances a novel, dual-inhibitor into Phase 3 for AKC, a chronic inflammatory eye disease with no FDA-approved treatment options.
Uncategorized
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
Levodopa May Help Prevent Progression to Neovascular AMD
A new study shows that in patients with intermediate nonneovascular age-related macular degeneration, levodopa treatment is linked to a lower risk of developing the neovascular form of the disease. Medscape Medical News
Heart Risks May Rise and Persist After Transient Vision Loss
Transient loss of vision is associated with an increased risk for cardiovascular events within 14 days of diagnosis, and risks may persist for up to 10 years, a study finds. Medscape Medical News
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food an…